問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of Urology

Division of Hematology & Oncology

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

邱宗傑Chiou, Tzeon-jye
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱宗傑

List

85Cases

2018-01-15 - 2020-12-25

Phase III

A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

2008-01-31 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2005-12-01 - 2008-06-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-12-03 - 2018-09-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2008-03-20 - 2011-01-31

Phase III

A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINTM, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer

  • Condition/Disease

    Colorectal Cancer

  • Test Drug

    AZD2171

Participate Sites
4Sites

Terminated4Sites

2013-02-01 - 2020-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2015-06-22 - 2019-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

  • Condition/Disease

    Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Terminated7Sites

2014-04-07 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB